Pharmaceutical company Artelo completes a $9.475 million private sale, incorporating Solana into its reserve assets.

robot
Abstract generation in progress

On August 4, pharmaceutical company Artelo Biosciences (NASDAQ: ARTL) announced the completion of a $9.475 million private sale financing, which will be used to initiate a digital asset reserve strategy centered around Solana (SOL), becoming the first publicly traded pharmaceutical company to include SOL in its reserve assets.

The private sale includes the issuance of common stock (or pre-paid warrants) at a price of $10.45 per share, as well as two batches of three-year warrants with exercise prices of $10.20 and $50, respectively. The transaction is expected to be completed on August 5, 2025.

SOL4.07%
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • 6
  • Share
Comment
0/400
AirdropHunterXMvip
· 10h ago
sol is the best in the world
View OriginalReply0
MemeCuratorvip
· 10h ago
It feels like this pharmaceutical company is going bankrupt.
View OriginalReply0
Web3Educatorvip
· 10h ago
fascinating case study for my blockchain economics seminar next week
Reply0
ColdWalletGuardianvip
· 10h ago
Is the pharmaceutical factory trading sol?
View OriginalReply0
SerumSurfervip
· 10h ago
The pharmaceutical factory is also involved.
View OriginalReply0
JustHodlItvip
· 10h ago
Is this all the reserves?
View OriginalReply0
Trade Crypto Anywhere Anytime
qrCode
Scan to download Gate app
Community
English
  • 简体中文
  • English
  • Tiếng Việt
  • 繁體中文
  • Español
  • Русский
  • Français (Afrique)
  • Português (Portugal)
  • Bahasa Indonesia
  • 日本語
  • بالعربية
  • Українська
  • Português (Brasil)